TriSalus Life Sciences (TLSI) EBIT Margin (2022 - 2025)
Historic EBIT Margin for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to 77.94%.
- TriSalus Life Sciences' EBIT Margin rose 409800.0% to 77.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 77.74%, marking a year-over-year increase of 815500.0%. This contributed to the annual value of 122.88% for FY2024, which is 1714000.0% up from last year.
- As of Q3 2025, TriSalus Life Sciences' EBIT Margin stood at 77.94%, which was up 409800.0% from 65.39% recorded in Q2 2025.
- In the past 5 years, TriSalus Life Sciences' EBIT Margin ranged from a high of 65.39% in Q2 2025 and a low of 364.91% during Q4 2022
- For the 4-year period, TriSalus Life Sciences' EBIT Margin averaged around 191.69%, with its median value being 180.77% (2024).
- Per our database at Business Quant, TriSalus Life Sciences' EBIT Margin tumbled by -1517300bps in 2023 and then skyrocketed by 2395700bps in 2024.
- Quarter analysis of 4 years shows TriSalus Life Sciences' EBIT Margin stood at 364.91% in 2022, then surged by 32bps to 249.05% in 2023, then soared by 63bps to 91.76% in 2024, then rose by 15bps to 77.94% in 2025.
- Its EBIT Margin was 77.94% in Q3 2025, compared to 65.39% in Q2 2025 and 79.95% in Q1 2025.